ONC201, as a dual AKT and ERK inhibitor, has shown promise in preclinical models and is now the first and only drug approved by the FDA for the treatment of recurrent pediatric and adult H3K27M-mutant diffuse midline glioma (DMG). This evidence concerns the gene AKT1 and diffuse midline glioma.